Abstract | BACKGROUND: METHODS AND RESULTS: Thirty-nine patients with intractable PAD were randomly assigned to 3 groups: a negative control group (n=12) treated with conventional drug therapy; a positive control group (n=13) treated with conventional drug therapy plus bone marrow transplantation (BMT); and a G-CSF group (n=14) treated with conventional therapy plus subcutaneous injection of 2-5 microg/kg of recombinant human G-CSF once daily for 10 days. One month after treatment, subjective symptoms improved significantly in the G-CSF and BMT groups. Ankle-brachial pressure index and transcutaneous oxygen pressure increased significantly in the BMT and G-CSF groups, but no such improvements were seen in the group receiving conventional therapy alone. CONCLUSIONS:
G-CSF improves the clinical signs and symptoms of patients with intractable PAD to the same degree as BMT does. This noninvasive treatment may thus represent a useful new approach to managing the disease.
|
Authors | Masazumi Arai, Yu Misao, Hiroshi Nagai, Masanori Kawasaki, Kenshi Nagashima, Koji Suzuki, Kunihiko Tsuchiya, Setsuko Otsuka, Yoshihiro Uno, Genzou Takemura, Kazuhiko Nishigaki, Shinya Minatoguchi, Hisayoshi Fujiwara |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 70
Issue 9
Pg. 1093-8
(Sep 2006)
ISSN: 1346-9843 [Print] Japan |
PMID | 16936417
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
|
Topics |
- Aged
- Atherosclerosis
(therapy)
- Bone Marrow Transplantation
- Female
- Granulocyte Colony-Stimulating Factor
(administration & dosage)
- Hematopoietic Stem Cell Mobilization
(methods)
- Humans
- Male
- Middle Aged
- Recombinant Proteins
- Regeneration
(drug effects)
- Remission Induction
- Transplantation, Autologous
|